Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053761 | 0.85 | BRD4 (0.48) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL17156668 | 0.85 | BRD4 (0.41) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL1516488 | 0.78 | BRD4 (0.39) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL393972 | 0.76 | MAP2K1 (0.46) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL16083401 | 0.74 | BRD4 (0.54) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL10251549 | 0.73 | BRD4 (0.53) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL16153829 | 0.73 | BRD4 (0.45) | BRD4L3MBTL1KMT2AMEN1MAP2K1 | |
| SCHEMBL7928003 | 0.72 | NOTUM (0.40) | KMT2AMEN1POLBNOTUMALDH1A1 | |
| SCHEMBL2975718 | 0.72 | KMT2A (0.60) | BRD4L3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL2976076 | 0.72 | TP53 (0.39) | BRD4L3MBTL1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970258-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | disclosed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9163019-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-20 | — | — | US | disclosed |
| US-20140303153-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303153-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | BRD4 4484/4885L3MBTL1 3920/4885KMT2A 2130/4885 |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | BRD4 4484/4885L3MBTL1 3920/4885KMT2A 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.